Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33. Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its...
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with...
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0716 | -9.4872134623 | 0.7547 | 0.7665 | 0.63 | 840350 | 0.6653019 | CS |
4 | -0.2759 | -28.7695516163 | 0.959 | 1.19 | 0.63 | 1853231 | 0.90722707 | CS |
12 | -0.2969 | -30.2959183673 | 0.98 | 1.19 | 0.63 | 882494 | 0.9006543 | CS |
26 | -1.4669 | -68.2279069767 | 2.15 | 2.23 | 0.63 | 560399 | 1.05836327 | CS |
52 | -1.4269 | -67.6255924171 | 2.11 | 3.1399 | 0.63 | 394051 | 1.36270993 | CS |
156 | -14.8769 | -95.6098971722 | 15.56 | 18.515 | 0.63 | 217572 | 3.2342972 | CS |
260 | -41.3369 | -98.3743455497 | 42.02 | 63.62 | 0.63 | 212713 | 7.41781842 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관